Dr. Barney Sparrow
Dr. Barney Sparrow has been named the new Principal Investigator for Battelle’s work on the National Institute of Environmental Health Science’s National Toxicology Program (NTP). In his new role, he will be responsible for oversight and direction of in vivo toxicology research that will provide critical insights into the toxicological profiles and potential human health impacts of dozens of chemicals that are already in widespread use.
Barney brings more than 19 years of toxicology experience to his new role. Since joining Battelle in 2001, he has led numerous toxicology testing and drug development programs utilizing various routes of exposure (including inhalation, oral, dermal, intravenous, subcutaneous and intradermal) and a diverse range of test systems. He has served as Study Director for more than 50 non-clinical studies for numerous commercial and government clients. For the past seven years, he has managed up to 40 technical staff and more than 35 professional staff who are responsible for executing GLP preclinical toxicology studies.
As the Principal Investigator for the NTP, Barney will serve as the main point of contact for the National Institute of Environmental Health and other partner agencies and contractors, and oversee all Battelle work conducted as part of the Support of the Research Effort to Evaluate the Toxic and Carcinogenic Potential of Test Agents contract. Battelle has been a prime contractor for the NTP for more than 25 years and is currently in year two of a 10-year contract to continue this work. According to the NTP, more than 80,000 chemicals are registered for use in the United States and an estimated 2,000 new ones are introduced each year for use in everyday items such as foods and beverages, personal care products, prescription drugs, household cleaners and lawn care products. The NTP studies aim to fill the gaps in our understanding about the human health impacts of these substances, including their carcinogenic potential and impact on the immune, reproductive, metabolic and other body systems.
Barney also currently serves as the Principal Investigator for the Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs) programs, which focus on “orphan drugs” to treat serious but rare diseases that do not have the market potential to attract private investment.
Barney holds a Ph.D. in Toxicology from Oregon State University and B.S. degrees in Biology and Chemistry from the College of Great Falls, and is a Diplomat for the American College of Toxicology (D.A.B.T.). He has authored or co-authored a number of publications and been involved in numerous presentations of study findings over the years. Prior to coming to Battelle, he worked as a Research Biologist for DOW Chemical and completed a Postdoctoral Fellowship with the U.S. Environmental Protection Agency.